¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29
±³À°ÀÏÀÚ : 2024-06-29
±³À°Àå¼Ò : ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë

±³À°ÁÖÁ¦ : 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼҾƺñ´¢ÀÇÇÐȸ

´ã´çÀÚ : À̼¼Èñ
¿¬¶ôó : 02-573-8190

À̸ÞÀÏ : urology@urology.or.kr

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 2Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 22,000¿ø  

ºñ°í ȸºñ ³³ºÎ¿¡ µû¶ó Â÷µî ºÎ°úÇÒ ¼ö ÀÖÀ½


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:00~09:30 Enuresis and nocturia in an adolescence ±è¼ºÃ¶, °íÇõÁØ(¿ï»êÀÇ´ë, µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:30~10:00 Overactive bladder and urinary incontinence symptoms in an adolescence ÀÓ¿µÀç, ±èµ¿¼ö(¼­¿ïÀÇ´ë, °æÈñÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:00~10:30 Panel discussion ()

ÈÞ½Ä 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:30~10:50 Break ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:50~11:10 Management of ureterocele ÇÏÁö¿ë(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:10~11:30 Management of ureteropelvic junction obstruction (UPJO) ¹èÀçÇö(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:30~12:00 Panel discussion ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:00~12:15 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In children(KSPU) ¼Û»óÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:15~12:30 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In adult(KCS) ¹èÈ£¿µ(¿ï»êÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø ½Å°æ¿Ü°ú ¿¬¼ö°­Á : 2024-06-29
´ÙÀ½±Û 2024³â ´ëÇѳëÀνŰæÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
437 ¼­¿ï °Ç±¹´ëÇб³º´¿ø ´ëÇѳú½Å°æÀçÈ°ÇÐȸ 2018³âµµ ¿öÅ©¼ó : 2018-09-15 0 625 2018-08-15
436 ¼­¿ï °Ç±¹´ëÇб³º´¿ø ´ëÇѳú½Å°æÀçÈ°ÇÐȸ 2018³âµµ Ã߰迬¼ö°­Á : 2018-09-15 0 352 2018-08-15
435 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ The 17th Postgraduate Course of Diabetes : 2018-09-15 0 848 2018-08-15
434 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-15 0 890 2018-08-15
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 966 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,518 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 974 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 774 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 632 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,484 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,551 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 515 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 519 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 809 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷